Emergent Drug Patent Portfolio
Emergent owns 1 orange book drug protected by 8 US patents Given below is the list of Emergent's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10085937 | Nasal drug products and methods of their use | 16 Mar, 2035 | Active |
| US9211253 | Nasal drug products and methods of their use | 16 Mar, 2035 | Active |
| US9468747 | Nasal drug products and methods of their use | 16 Mar, 2035 | Active |
| US9480644 | Nasal drug products and methods of their use | 16 Mar, 2035 | Active |
| US9561177 | Nasal drug products and methods of their use | 16 Mar, 2035 | Active |
| US9629965 | Nasal drug products and methods of their use | 16 Mar, 2035 | Active |
| US9707226 | Nasal drug products and methods of their use | 16 Mar, 2035 | Active |
| US9775838 | Nasal drug products and methods of their use | 16 Mar, 2035 | Active |
Latest Legal Activities on Emergent's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Emergent.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 17 Apr, 2024 | US9480644 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 31 May, 2023 | US9211253 (Litigated) |
| Payment of Maintenance Fee, 4th Year, Large Entity | 16 Mar, 2022 | US10085937 |
| Review Certificate Mailed | 24 Aug, 2021 | US9629965 |
| Review Certificate Mailed | 23 Aug, 2021 | US9211253 (Litigated) |
| Review Certificate | 05 Aug, 2021 | US9211253 (Litigated) |
| Review Certificate | 05 Aug, 2021 | US9629965 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 17 Mar, 2021 | US9775838 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 06 Jan, 2021 | US9707226 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 25 Sep, 2020 | US9629965 |
| Termination or Final Written Decision | 21 Aug, 2020 | US9211253 (Litigated) |
| Termination or Final Written Decision | 21 Aug, 2020 | US9629965 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 23 Jul, 2020 | US9561177 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 16 Apr, 2020 | US9480644 |
|
Request for Trial Denied
Critical
| 16 Oct, 2019 | US9775838 |
Emergent's Drug Patent Litigations
Emergent's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Feb 19, 2019, against patent number US9561177. The petitioner Nalox-1 Pharmaceuticals, LLC et al., challenged the validity of this patent, with Opiant Pharmaceuticals, Inc. as the respondent. Click below to track the latest information on how companies are challenging Emergent's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US9211253 | February, 2019 |
Final Written Decision
(21 Aug, 2020)
| Opiant Pharmaceuticals, Inc. | Nalox-1 Pharmaceuticals, LLC et al. |
| US9468747 | February, 2019 |
Final Written Decision
(21 Aug, 2020)
| Opiant Pharmaceuticals, Inc. | Nalox-1 Pharmaceuticals, LLC et al. |
| US9629965 | February, 2019 |
Final Written Decision
(21 Aug, 2020)
| Opiant Pharmaceuticals, Inc. | Nalox-1 Pharmaceuticals, LLC et al. |
| US9775838 | February, 2019 |
Institution Denied
(16 Oct, 2019)
| Opiant Pharmaceuticals, Inc. | Nalox-1 Pharmaceuticals, LLC et al. |
| US9629965 | February, 2019 |
Institution Denied
(01 Oct, 2019)
| Opiant Pharmaceuticals, Inc. | Nalox-1 Pharmaceuticals, LLC et al. |
| US9468747 | February, 2019 |
Institution Denied
(09 Sep, 2019)
| Opiant Pharmaceuticals, Inc. | Nalox-1 Pharmaceuticals, LLC et al. |
| US9211253 | February, 2019 |
Institution Denied
(27 Aug, 2019)
| Opiant Pharmaceuticals, Inc. | Nalox-1 Pharmaceuticals, LLC et al. |
| US9561177 | February, 2019 |
Institution Denied
(27 Aug, 2019)
| Opiant Pharmaceuticals, Inc. | Nalox-1 Pharmaceuticals, LLC et al. |
Emergent's Family Patents
Emergent Drug List
Given below is the complete list of Emergent's drugs and the patents protecting them.
1. Narcan
Narcan is protected by 8 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10085937 | Nasal drug products and methods of their use |
16 Mar, 2035
(9 years from now)
| Active |
| US9211253 | Nasal drug products and methods of their use |
16 Mar, 2035
(9 years from now)
| Active |
| US9468747 | Nasal drug products and methods of their use |
16 Mar, 2035
(9 years from now)
| Active |
| US9480644 | Nasal drug products and methods of their use |
16 Mar, 2035
(9 years from now)
| Active |
| US9561177 | Nasal drug products and methods of their use |
16 Mar, 2035
(9 years from now)
| Active |
| US9629965 | Nasal drug products and methods of their use |
16 Mar, 2035
(9 years from now)
| Active |
| US9707226 | Nasal drug products and methods of their use |
16 Mar, 2035
(9 years from now)
| Active |
| US9775838 | Nasal drug products and methods of their use |
16 Mar, 2035
(9 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Narcan's drug page